TABLE 1.
Baseline characteristics of study cohorts
| Cohort | N | f-u, y | European, % | Female, % | Stratum | Age, year old | Duration, y | LD, % | DA, % |
|---|---|---|---|---|---|---|---|---|---|
| PPMI | 408 | 7.0 | 95.1 | 34.6 | Male | 62.15 (9.86) | 0.53 (0.49) | – | – |
| Female | 60.76 (9.60) | 0.60 (0.63) | |||||||
| PreCEPT_PostCEPT | 390 | 6.9 | 97.7 | 33.8 | Male | 59.83 (9.51) | 0.79 (0.80) | – | – |
| Female | 60.96 (9.56) | 0.84 (0.85) | |||||||
| PARKWEST | 181 | 5.0 | 100 | 37.8 | Male | 67.82 (9.21) | 0.16 (0.10) | – | – |
| Female | 68.36 (9.10) | 0.20 (0.14)* | |||||||
| DATATOP | 796 | 1.1 | 97.7 | 33.7 | Male | 61.45 (9.35) | 1.16 (1.14) | – | – |
| Female | 60.34 (9.80) | 1.10 (1.05) | |||||||
| PICNICS | 122 | 3.5 | 98.4 | 35.2 | Male | 67.85 (8.40) | 0.30 (0.49) | 30.4 | 17.7 |
| Female | 67.93 (10.28) | 0.12 (0.50)* | 27.9 | 23.3 | |||||
| NET_PD_LS1 | 1705 | 4.0 | 92.7 | 35.7 | Male | 62.07 (9.32) | 1.55 (1.08) | 57.5 | 60.4 |
| Female | 61.20 (10.06) | 1.54 (1.10) | 55.3 | 63.3 | |||||
| DIGPD | 350 | 3.0 | 85.8 | 39.4 | Male | 61.45 (10.34) | 2.55 (1.52) | 65.6 | 77.8 |
| Female | 62.40 (9.61) | 2.46 (1.59) | 62.3 | 63.0 | |||||
| PDBP | 486 | 3.0 | 93.0 | 39.7 | Male | 65.03 (9.13) | 5.31 (4.74) | 81.9 | 50.2* |
| Female | 64.87 (8.67) | 5.22 (4.78) | 76.9 | 56.8 | |||||
| HBS | 482 | 1.9 | 96.3 | 35.3 | Male | 65.79 (9.67) | 4.28 (4.79) | 73.7 | 39.4 |
| Female | 66.60 (9.40) | 3.97 (4.30) | 70.0 | 42.4 | |||||
| PROPARK | 327 | 5.0 | NA | 33.9 | Male | 59.56 (10.29) | 6.48 (5.00) | 67.1 | 69.9 |
| Female | 59.51 (11.63) | 6.98 (4.18) | 64.0 | 79.3 | |||||
| PARKFIT | 466 | 2.0 | NA | 33.3 | Male | 65.28 (7.41) | 4.97 (4.25) | NA | NA |
| Female | 65.49 (7.60) | 5.38 (4.76) | |||||||
| UDALL_PENN | 233 | 4.0 | 94.4 | 30.9 | Male | 70.53 (7.29) | 5.73 (4.96) | 84.5 | 46.0 |
| Female | 70.14 (8.15) | 6.64 (5.80) | 90.3 | 56.9 | |||||
| Fox Insight (non-PD) | 7588 | – | 95.8 | 78.8 | Male | 63.55 (7.89) | – | – | – |
| Female | 62.51 (7.39)* | ||||||||
| Fox Insight (PD) | 17 719 | – | 96.4 | 45 | Male | 66.72 (7.16) | 4.61 (3.24) | 80.3 | 29.4 |
| Female | 66.00 (7.10)* | 4.50 (3.25)* | 76.8* | 35.0* |
f-u, median follow-up period; European, European descent; Duration, mean disease duration; LD, levedopa use; DA, dopamine agonist use. Age, mean (standard deviation).
P < 0.05 for t test comparing with male versus female.
Abbreviations: DATATOP, Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism; DIGPD, Drug Interaction with Genes in Parkinson’s Disease; HBS, Harvard Biomarkers Study; NET-PD_LS1, NIH Exploratory Trials in Parkinson’s Disease Large Simple Study 1; PARKFIT, ParkFit study; PARKWEST, The Norwegian ParkWest study; PDBP, Parkinson’s Disease Biomarker Program; PICNICS, Parkinsonism Incidence and Cognitive and Non-motor heterogeneity In Cambridgeshire; PPMI, Parkinson’s Progression Markers Initiative; PreCEPT_PostCEPT, Parkinson Research Examination of CEP-1347 Trial and PostCEPT; PROPARK, Profiling Parkinson’s disease study; and UDALL_PENN, Morris K. Udall Centers for Parkinson’s Research.